A genetically engineered herpes virus, designed specifically to infect and destroy cancer cells while training the immune system to attack tumors elsewhere in the body, won FDA approval on August 6, 2026, for a group of melanoma patients who had run out of other options. The approval capped a genuinely unusual regulatory journey: the same therapy had already been rejected twice by the FDA within the previous 13 months.

A virus engineered specifically to fight cancer

The therapy, called Tudriqev, carries the generic name vusolimogene oderparepvec-wtpg and was previously known during its development simply as RP1. It is built from herpes simplex virus type 1, the common virus responsible for cold sores, but genetically modified in two specific ways to turn it into a cancer treatment. According to its manufacturer, Replimune, the virus has been engineered to encode a fusogenic glycoprotein derived from gibbon ape leukemia virus, which helps the virus spread more effectively between cancer cells, and to produce human granulocyte macrophage colony-stimulating factor, a molecule that helps recruit and activate immune cells at the tumor site. The genes responsible for the herpes virus's natural neurovirulence, its ability to cause disease in nerve tissue, have been deleted, a modification designed to make the virus safe to inject directly into tumors while preserving its cancer-killing and immune-stimulating properties.

This category of treatment, known as oncolytic viral therapy, works through a genuinely different mechanism than most existing cancer drugs. Rather than simply poisoning rapidly dividing cells the way traditional chemotherapy does, the modified virus infects and destroys cancer cells directly while it replicates within the tumor, and the resulting cell destruction releases tumor material in a way that can help train the broader immune system to recognize and attack cancer cells throughout the body, not just at the injection site.

Who the approval actually covers

Tudriqev received FDA approval specifically in combination with nivolumab, sold under the brand name Opdivo, for adult patients with unresectable advanced cutaneous melanoma who experienced disease progression despite already receiving a PD-1-blocking antibody-based treatment regimen. That's a clinically significant restriction: this approval targets patients who have already failed the current standard immunotherapy approach for advanced melanoma, a group that, according to Michael K. Wong, the IGNYTE trial's primary investigator and former physician in chief at Roswell Park Comprehensive Cancer Center, faces "few options after anti-PD-1 therapy" along with "high morbidity and poor survival outcomes."

That framing matters because it places Tudriqev in a genuinely underserved treatment gap. Patients who progress after standard immunotherapy for melanoma have historically had limited subsequent treatment options with strong evidence behind them, making any therapy demonstrating meaningful response rates in this specific population clinically significant regardless of how it compares to first-line treatments.

What the supporting trial data actually showed

The approval rests on data from the IGNYTE trial, an open-label, multiregional, single-arm study that enrolled 140 adult patients with stage IIIB, IIIC, or IV unresectable advanced melanoma. All participants had experienced confirmed disease progression after at least eight consecutive weeks of prior anti-PD-1-based therapy, with or without accompanying anti-CTLA-4 treatment. Among the 91 patients within that group who had at least one non-injected lesion, meaning cancer present at sites beyond where the virus was directly administered, the combination of Tudriqev and nivolumab produced an objective response rate of 24.2%, roughly one in four patients, with a median duration of response of 14.1 months.

That non-injected lesion detail carries real scientific significance. Because Tudriqev works partly by direct injection into accessible tumors, measuring its effect specifically on lesions the drug was never physically injected into offers stronger evidence that the treatment is genuinely triggering a broader, immune-system-mediated anti-cancer response, rather than simply destroying whatever tumor tissue it happens to come into direct physical contact with.

Why the FDA said no twice before saying yes

Tudriqev's path to approval was anything but smooth. The FDA had previously issued two separate complete response letters rejecting the therapy within the prior 13 months, with the most recent rejection coming in April 2026 specifically over concerns regarding the trial's design and the strength of its effectiveness evidence, given that IGNYTE was a single-arm study without a traditional randomized comparison group.

That regulatory tension came to a head on July 30, 2026, when the FDA convened its Cellular, Tissue, and Gene Therapies Advisory Committee to formally reconsider the application, including a public hearing session featuring input from patients, patient advocates, clinicians, and independent experts. The committee ultimately voted 10 to 3 to affirm that the IGNYTE trial's results were clinically meaningful, providing regulators the outside expert backing needed to finally approve the therapy roughly a week later.

An approval that comes with strings attached

Tudriqev's clearance came through the FDA's accelerated approval pathway, based specifically on objective response rate and duration of response rather than the kind of longer-term survival data typically required for standard, full approval. As a condition of that accelerated pathway, Replimune is required to conduct post-approval confirmatory trials verifying the therapy's actual clinical benefit, and continued marketing approval remains contingent on those confirmatory results holding up. The company has already launched a dedicated phase 3 confirmatory trial, called IGNYTE-3, specifically designed to satisfy that requirement going forward.

That structure means Tudriqev's approval, while a genuine milestone for patients with treatment-resistant melanoma, is not necessarily permanent in its current form. If the confirmatory IGNYTE-3 trial fails to verify meaningful clinical benefit down the line, the FDA retains authority to reconsider the approval, a standard feature of the accelerated approval pathway designed to balance faster patient access against the reduced certainty that comes with approving a drug based on response rate data rather than confirmed survival benefit.

What this means for patients right now

For melanoma patients who have already progressed through standard PD-1-based immunotherapy, Tudriqev represents a genuinely new treatment class now available in the clinic rather than confined to trial enrollment. Replimune has launched a patient support program called ReplimuneConnect Plus specifically to help patients navigate access, insurance reimbursement, and financial assistance as the therapy begins reaching oncology practices.

For oncology providers, the approval introduces meaningful new logistical considerations, since oncolytic viral therapy involves localized injection protocols and specific biosafety handling requirements that differ considerably from administering a standard infused or oral cancer drug, requirements that clinical teams will need to build familiarity with as this new therapeutic class becomes part of standard advanced melanoma treatment workflows.

Why a twice-rejected drug matters beyond melanoma specifically

Beyond its direct clinical impact, Tudriqev's approval carries broader significance for the oncolytic virus field as a treatment category generally. The therapy's initial rejections and eventual approval reflect the genuine regulatory tension surrounding single-arm trial designs in oncology, where drugs targeting rare or treatment-resistant patient populations often cannot ethically or practically be tested against a placebo control group, forcing regulators to weigh strong response rate signals against the inherent uncertainty of trials lacking a traditional randomized comparison.

Tudriqev's ultimate approval, following genuine scientific pushback and a formal advisory committee review, offers something of a template for how other oncolytic virus therapies currently in development might eventually navigate similar regulatory hurdles, provided their own trial data proves similarly durable and clinically meaningful once independent experts examine it closely.

---

*Sources cited in this article include the FDA's official press announcement dated August 6, 2026, Replimune's corporate press release, and reporting from Healio, Oncology Nursing News, Oncology Nursing Society, and BioPharm International covering the accelerated approval of Tudriqev (vusolimogene oderparepvec-wtpg). All figures reflect reporting available as of August 9, 2026.*